Biological evaluation of novel 5-((1H-indol-3-yl) methyl)-2-(4-chlorobenzyl)-6-phenyl-imidazo[2,1-b][13,4]thiadiazole derivatives as novel BCL-2 specific inhibitors

Antiapoptotic protein BCL2 is known to be upregulated in several cancer cells and therefore, it is an excellent target for cancer therapy. Previously, we reported a novel BCL2 inhibitor, Disarib, which inhibited BCL2 by predominantly binding to its BH1 domain and exhibited platelet-sparing ability l...

Full description

Saved in:
Bibliographic Details
Main Authors: Shivangi Sharma, Sadashivamurthy Shamanth, Humaira Siddiqua, Laijau Goyary, Kunigal S. Sagar, Susmita Kumari, Divya Sathees, Gudapureddy Radha, Bibha Choudhary, Sathees C. Raghavan, Kempegowda Mantelingu
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:European Journal of Medicinal Chemistry Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2772417425000032
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832582118006325248
author Shivangi Sharma
Sadashivamurthy Shamanth
Humaira Siddiqua
Laijau Goyary
Kunigal S. Sagar
Susmita Kumari
Divya Sathees
Gudapureddy Radha
Bibha Choudhary
Sathees C. Raghavan
Kempegowda Mantelingu
author_facet Shivangi Sharma
Sadashivamurthy Shamanth
Humaira Siddiqua
Laijau Goyary
Kunigal S. Sagar
Susmita Kumari
Divya Sathees
Gudapureddy Radha
Bibha Choudhary
Sathees C. Raghavan
Kempegowda Mantelingu
author_sort Shivangi Sharma
collection DOAJ
description Antiapoptotic protein BCL2 is known to be upregulated in several cancer cells and therefore, it is an excellent target for cancer therapy. Previously, we reported a novel BCL2 inhibitor, Disarib, which inhibited BCL2 by predominantly binding to its BH1 domain and exhibited platelet-sparing ability like ABT199, the only FDA-approved BCL2 inhibitor. Here, we have synthesized the novel Disarib derivatives where oxindole moiety in Disarib was replaced with indole and evaluated their biological activity. We report several derivatives of Disarib and the identification of DSR 43 and 4-OCH3, as the most potent among them. Treatment of cancer cell lines with the Disarib derivatives, DSR 43 and 4-OCH3 led to the activation of the apoptotic pathway without generating any ROS or disrupting the mitochondrial membrane potential within the cells, leading to cell death. Western blot analysis in tandem with Annexin V/PI staining confirmed the activation of apoptosis. In silico studies, using derivatives suggests a promising therapeutic window with less off-target effects. Furthermore, their efficacy across different cancer cell lines highlights their broad potential as anticancer agents. Taken together, our results suggest that Disarib derivatives may have the potential to be developed as cancer therapeutic.
format Article
id doaj-art-b1ce7f9b665843aa999f9b985a0def8c
institution Kabale University
issn 2772-4174
language English
publishDate 2025-04-01
publisher Elsevier
record_format Article
series European Journal of Medicinal Chemistry Reports
spelling doaj-art-b1ce7f9b665843aa999f9b985a0def8c2025-01-30T05:15:12ZengElsevierEuropean Journal of Medicinal Chemistry Reports2772-41742025-04-0113100247Biological evaluation of novel 5-((1H-indol-3-yl) methyl)-2-(4-chlorobenzyl)-6-phenyl-imidazo[2,1-b][13,4]thiadiazole derivatives as novel BCL-2 specific inhibitorsShivangi Sharma0Sadashivamurthy Shamanth1Humaira Siddiqua2Laijau Goyary3Kunigal S. Sagar4Susmita Kumari5Divya Sathees6Gudapureddy Radha7Bibha Choudhary8Sathees C. Raghavan9Kempegowda Mantelingu10Department of Biochemistry, Indian Institute of Science, Bangalore, 560012, IndiaDepartment of Chemistry, Manasagangotri, University of Mysore, Mysuru, Karnataka, India, 570006Department of Biochemistry, Indian Institute of Science, Bangalore, 560012, IndiaDepartment of Biochemistry, Indian Institute of Science, Bangalore, 560012, IndiaDepartment of Chemistry, BMS College of Engineering, Bangalore, 560 019, IndiaDepartment of Biochemistry, Indian Institute of Science, Bangalore, 560012, IndiaDepartment of Biochemistry, Indian Institute of Science, Bangalore, 560012, India; St Joseph's University, Bangalore, 560027, IndiaDepartment of Biochemistry, Indian Institute of Science, Bangalore, 560012, IndiaInstitute of Bioinformatics and Applied Biotechnology, Biotech Park, Electronic City Phase I, Bangalore, 560100, IndiaDepartment of Biochemistry, Indian Institute of Science, Bangalore, 560012, India; Corresponding author. Department of Biochemistry, Indian Institute of Science, Bangalore, 560012, India.Department of Chemistry, Manasagangotri, University of Mysore, Mysuru, Karnataka, India, 570006; Corresponding author. Department of Chemistry, Manasagangotri, University of Mysore, Mysuru, 570006, India.Antiapoptotic protein BCL2 is known to be upregulated in several cancer cells and therefore, it is an excellent target for cancer therapy. Previously, we reported a novel BCL2 inhibitor, Disarib, which inhibited BCL2 by predominantly binding to its BH1 domain and exhibited platelet-sparing ability like ABT199, the only FDA-approved BCL2 inhibitor. Here, we have synthesized the novel Disarib derivatives where oxindole moiety in Disarib was replaced with indole and evaluated their biological activity. We report several derivatives of Disarib and the identification of DSR 43 and 4-OCH3, as the most potent among them. Treatment of cancer cell lines with the Disarib derivatives, DSR 43 and 4-OCH3 led to the activation of the apoptotic pathway without generating any ROS or disrupting the mitochondrial membrane potential within the cells, leading to cell death. Western blot analysis in tandem with Annexin V/PI staining confirmed the activation of apoptosis. In silico studies, using derivatives suggests a promising therapeutic window with less off-target effects. Furthermore, their efficacy across different cancer cell lines highlights their broad potential as anticancer agents. Taken together, our results suggest that Disarib derivatives may have the potential to be developed as cancer therapeutic.http://www.sciencedirect.com/science/article/pii/S2772417425000032Cancer therapyBCL2DisaribABT199ApoptosisAnticancer drug
spellingShingle Shivangi Sharma
Sadashivamurthy Shamanth
Humaira Siddiqua
Laijau Goyary
Kunigal S. Sagar
Susmita Kumari
Divya Sathees
Gudapureddy Radha
Bibha Choudhary
Sathees C. Raghavan
Kempegowda Mantelingu
Biological evaluation of novel 5-((1H-indol-3-yl) methyl)-2-(4-chlorobenzyl)-6-phenyl-imidazo[2,1-b][13,4]thiadiazole derivatives as novel BCL-2 specific inhibitors
European Journal of Medicinal Chemistry Reports
Cancer therapy
BCL2
Disarib
ABT199
Apoptosis
Anticancer drug
title Biological evaluation of novel 5-((1H-indol-3-yl) methyl)-2-(4-chlorobenzyl)-6-phenyl-imidazo[2,1-b][13,4]thiadiazole derivatives as novel BCL-2 specific inhibitors
title_full Biological evaluation of novel 5-((1H-indol-3-yl) methyl)-2-(4-chlorobenzyl)-6-phenyl-imidazo[2,1-b][13,4]thiadiazole derivatives as novel BCL-2 specific inhibitors
title_fullStr Biological evaluation of novel 5-((1H-indol-3-yl) methyl)-2-(4-chlorobenzyl)-6-phenyl-imidazo[2,1-b][13,4]thiadiazole derivatives as novel BCL-2 specific inhibitors
title_full_unstemmed Biological evaluation of novel 5-((1H-indol-3-yl) methyl)-2-(4-chlorobenzyl)-6-phenyl-imidazo[2,1-b][13,4]thiadiazole derivatives as novel BCL-2 specific inhibitors
title_short Biological evaluation of novel 5-((1H-indol-3-yl) methyl)-2-(4-chlorobenzyl)-6-phenyl-imidazo[2,1-b][13,4]thiadiazole derivatives as novel BCL-2 specific inhibitors
title_sort biological evaluation of novel 5 1h indol 3 yl methyl 2 4 chlorobenzyl 6 phenyl imidazo 2 1 b 13 4 thiadiazole derivatives as novel bcl 2 specific inhibitors
topic Cancer therapy
BCL2
Disarib
ABT199
Apoptosis
Anticancer drug
url http://www.sciencedirect.com/science/article/pii/S2772417425000032
work_keys_str_mv AT shivangisharma biologicalevaluationofnovel51hindol3ylmethyl24chlorobenzyl6phenylimidazo21b134thiadiazolederivativesasnovelbcl2specificinhibitors
AT sadashivamurthyshamanth biologicalevaluationofnovel51hindol3ylmethyl24chlorobenzyl6phenylimidazo21b134thiadiazolederivativesasnovelbcl2specificinhibitors
AT humairasiddiqua biologicalevaluationofnovel51hindol3ylmethyl24chlorobenzyl6phenylimidazo21b134thiadiazolederivativesasnovelbcl2specificinhibitors
AT laijaugoyary biologicalevaluationofnovel51hindol3ylmethyl24chlorobenzyl6phenylimidazo21b134thiadiazolederivativesasnovelbcl2specificinhibitors
AT kunigalssagar biologicalevaluationofnovel51hindol3ylmethyl24chlorobenzyl6phenylimidazo21b134thiadiazolederivativesasnovelbcl2specificinhibitors
AT susmitakumari biologicalevaluationofnovel51hindol3ylmethyl24chlorobenzyl6phenylimidazo21b134thiadiazolederivativesasnovelbcl2specificinhibitors
AT divyasathees biologicalevaluationofnovel51hindol3ylmethyl24chlorobenzyl6phenylimidazo21b134thiadiazolederivativesasnovelbcl2specificinhibitors
AT gudapureddyradha biologicalevaluationofnovel51hindol3ylmethyl24chlorobenzyl6phenylimidazo21b134thiadiazolederivativesasnovelbcl2specificinhibitors
AT bibhachoudhary biologicalevaluationofnovel51hindol3ylmethyl24chlorobenzyl6phenylimidazo21b134thiadiazolederivativesasnovelbcl2specificinhibitors
AT satheescraghavan biologicalevaluationofnovel51hindol3ylmethyl24chlorobenzyl6phenylimidazo21b134thiadiazolederivativesasnovelbcl2specificinhibitors
AT kempegowdamantelingu biologicalevaluationofnovel51hindol3ylmethyl24chlorobenzyl6phenylimidazo21b134thiadiazolederivativesasnovelbcl2specificinhibitors